Can acitretin be safely used for long‑term treatment of psoriasis in adults who are not pregnant and have normal liver, lipid, and renal function without contraindicating conditions?

Can Acitretin Be Safely Given Long-Term for Psoriasis?

Yes, acitretin can be safely used for long-term management of psoriasis in appropriately selected adults with proper monitoring, though it requires careful attention to specific adverse effects and is absolutely contraindicated in women of childbearing potential. 1

Patient Selection Criteria

Long-term acitretin is appropriate for:

• Adults with severe psoriasis unresponsive to topical therapies 2
• Men without contraindications 1
• Women who are clearly postmenopausal or have had a hysterectomy 2
• Patients with erythrodermic or pustular psoriasis variants (Level I-II evidence) 1

Absolute Contraindications

Women of childbearing potential must never receive acitretin due to severe teratogenicity that persists for 3 years after discontinuation. 1, 2 Acitretin converts to etretinate (half-life 168 days) especially with alcohol ingestion, extending teratogenic risk indefinitely. 1 Major fetal abnormalities include skeletal, craniofacial, CNS, cardiovascular, and auditory malformations. 1

Long-Term Safety Profile

Efficacy and Dosing

• Effective dose range: 25-50 mg daily with gradual escalation starting at 25-30 mg for 2-4 weeks 1
• Mean long-term dose in real-world practice: 19-25 mg/day 3, 4
• Response timeline: 3-6 months to reach peak effect 1
• Drug survival rates: 79% at 1 year, 69.5% at 2 years, 61.2% at 3 years, and 53.5% at 5 years 3

Common Manageable Side Effects

Nearly all patients experience mucocutaneous effects that are dose-dependent but rarely require discontinuation: 1

• Cheilitis (71.4% of patients) 5
• Xerosis and dry skin (62.5%) 5
• Palmoplantar skin peeling (37.2%) 5
• Epistaxis, nasal/oral dryness 1
• Hair loss (more common in women at doses >17.5 mg/day) 1
• Brittle nails 1

Serious Adverse Effects Requiring Monitoring

Hyperlipidemia (25-50% of patients) is the most common laboratory abnormality: 1

• Monitor fasting lipids every 2-4 weeks for first 2 months, then every 3 months 1
• Triglycerides >5 mmol/L require referral to lipidologist 1
• Triglycerides approaching or >10 mmol/L warrant immediate discontinuation due to pancreatitis risk (which has been fatal) 1
• Higher risk in patients with obesity, diabetes, or excessive alcohol intake 1

Hepatotoxicity is uncommon but requires monitoring: 1

• Transaminase elevation occurs in 13-16% of patients 1
• A prospective 2-year study with paired liver biopsies showed no biopsy-proven hepatotoxicity 6
• Monitor liver function tests every 2-4 weeks initially, then every 3 months 1
• Major increases suggest toxic hepatitis requiring prompt discontinuation 1

Skeletal effects are rare with low-dose therapy: 1

• Diffuse idiopathic skeletal hyperostosis (DISH) is rarely reported 1
• No X-ray-confirmed DISH cases in long-term low-dose studies 7
• Routine radiological screening is not recommended due to radiation risk and unpredictable ossification sites 1
• Obtain targeted X-rays only if patients become symptomatic 1

Monitoring Protocol

Initial phase (first 2 months): 1

• Liver function tests every 2-4 weeks
• Fasting lipids (cholesterol and triglycerides) every 2-4 weeks
• Blood glucose in diabetic patients

Maintenance phase: 1

• Liver function tests every 3 months
• Fasting lipids every 3 months
• Blood glucose monitoring in diabetics

Key Clinical Considerations

Alcohol must be completely avoided in women of childbearing potential (even if using contraception) as it promotes conversion to etretinate. 1 The exact amount of alcohol causing this conversion is unknown, making even unintentional exposure risky. 1

Drug interactions to avoid: 1

• Vitamin A supplementation (increases hypervitaminosis A risk)
• Methotrexate (increases hepatotoxicity risk)
• Tetracyclines (increases pseudotumor cerebri risk)

Combination therapy enhances efficacy and safety: 1

• Acitretin + phototherapy (UVB or PUVA) allows lower doses of both modalities
• When combined with PUVA, acitretin decreases squamous cell carcinoma incidence compared to PUVA alone 1

Real-World Evidence

Long-term, low-dose acitretin (mean 19.28 mg/day over 3.2 years) showed: 3

• No patients developed clinical cirrhosis
• No uncontrolled hyperlipidemia requiring discontinuation
• Only 9 of 104 patients withdrew due to side effects
• Higher drug survival than previous studies

A 2-year prospective study with 83 paired liver biopsies demonstrated: 6

• 59% showed no change
• 24% showed improvement
• 17% showed worsening (mostly mild changes)
• No correlation between liver function test abnormalities and biopsy changes

Common Pitfalls to Avoid

1. Never prescribe to women who might become pregnant within 3 years - this is the most critical safety concern 2
2. Don't ignore lipid elevations - severe hypertriglyceridemia can cause fatal pancreatitis 1
3. Don't routinely order skeletal X-rays - only obtain if symptomatic 1
4. Don't start at high doses - gradual escalation improves tolerability 1
5. Don't combine with vitamin A supplements or methotrexate 1